Transport update: project application extensions
Do not meet others, even friends or family.
You can spread the virus even if you don’t have symptoms.
Do not meet others, even friends or family.
You can spread the virus even if you don’t have symptoms.
Press release
A former Secure Training Centre will receive its first adult prisoners today as part of further work to temporarily expand the prison estate to protect the public and NHS during the Coronavirus pandemic.

This follows the installation of the first of 500 temporary, single occupancy cells which began three weeks ago. Over 300 have now been delivered to nine prisons.
Across the estate, prisons are moving towards single-cell accommodation, as much as possible, to limit the spread of infection and the number of deaths. The strong measures the Prison Service is taking – creating extra cells, limiting prisoner movement, releasing some prisoners early, isolating those with symptoms and quarantining new arrivals – are successfully limiting the transmission of the virus.
The latest modelling by Public Health England and HM Prison and Probation Service predicts a drastic reduction in the spread rates of the infection, with each case being passed on to less than one person – meaning lives should be saved and the NHS is being protected from the impact of widespread local outbreaks.
The former Medway Secure Training Centre, which closed in March, will be temporarily reopened as an annex to nearby HMP Rochester, housing up to 70 category D adult prisoners. It will be staffed by existing prison staff from local prisons in Kent.
Temporary cells have now been installed to serve HMPs Highpoint, Hollesley Bay and North Sea Camp. Installation continues at HMPs Askham Grange, Coldingley, Hatfield, Lindholme, Littlehey, Moorland and Wymott with plans to deliver to further prisons across the estate as required.
Published 29 April 2020
Press release
Queen approves nomination of the Reverend Prebendary William Peter Guy Hazlewood to the Suffragan See of Lewes.

The Queen has approved the nomination of the Reverend Prebendary William Peter Guy Hazlewood, Vicar of the United Benefice of Dartmouth and Dittisham and Honorary Canon at Exeter Cathedral, in the Diocese of Exeter, to the Suffragan See of Lewes, in the Diocese of Chichester, in succession to the Right Reverend Richard Jackson following his translation to the See of Hereford.
Published 29 April 2020
rapidly scaled-up national initiative will mean clinical trials could start in weeks rather than months
6 drugs entering clinical trials as part of national effort made possible by government, academia and industry working together
this will give an early indication of whether these drugs could save lives and improve the outcomes of the most vulnerable patients with COVID-19
Thousands of patients could benefit from potential treatments for COVID-19 that will be fast-tracked through a new national clinical trial, the Health and Care Secretary has today announced.
This platform will accelerate the development of new drugs for patients hospitalised with COVID-19, reducing the time taken to set up clinical studies for new therapies from months to just weeks and helping to ease pressure on the NHS and ultimately save lives.
6 potential drugs will initially enter the programme, with the first of these beginning phase 2 studies – the stage of a clinical trial focused on the testing of a drug on patients to assess how effective it is and side effects – across the UK imminently.
Announcing the news at today’s press conference, Health and Social Care Secretary Matt Hancock said:
“Currently no drugs in the world have been clinically proven to treat COVID-19.But our Therapeutics Taskforce has identified a number of promising candidates. Currently, 6 different treatments have been entered into national clinical trials and the first is ready to enter the next stage: a new early phase clinical trial platform that we are launching today.
This is a national effort made possible by government, academia and industry working together.”
Funded by the Department of Health and Social Care (DHSC) and the UK Research and Innovation (UKRI), this collaborative programme – known as the ACCORD (Accelerating COVID-19 Research & Development platform) – aims to get an early indication of drug treatments’ effectiveness in treating coronavirus and if positive results are seen, these drugs will advance rapidly into the large-scale trials currently in progress across the country.
ACCORD brings together a single, UK-wide clinical trial platform provided by the clinical research company IQVIA and the UK’s leading research expertise through the National Institute for Health Research (NIHR), to rapidly test potential drugs through early stage clinical trials and feed them into the UK’s large-scale COVID-19 studies such as the RECOVERY trial, currently the world’s largest randomised controlled clinical trial for COVID-19 treatment. It is reducing the time taken to set up clinical studies from months to just weeks.
ACCORD is part of a co-ordinated therapeutic development pathway that the government has put in place, overseen by the Department for Business, Energy and Industrial Strategy and delivered by the UKRI, as part of the overall Therapeutics Taskforce.
Business Secretary Alok Sharma said:
“The UK is home to world-class scientists and researchers who are united in their aim to defeat coronavirus.
“Through ACCORD, we are bringing together the government, industry and research organisations to speed up the development of effective new coronavirus treatments, helping to save thousands of people’s lives and benefiting our NHS.”
Further potential treatments will be rapidly fed into ACCORD as the programme rolls out over the next few weeks.
UK Research and Innovation Chief Executive, Professor Sir Mark Walport said:
“This initiative will rapidly test the most promising drugs in the fight against COVID-19. Bringing together expertise from across the UK’s world-class research and innovation sectors – from clinical researchers through to the pharmaceutical industry – this national platform will rapidly prioritise and deliver the best potential drugs into clinical trials to discover if they can help people with COVID-19.”
ACCORD has been made possible by partnership working between the Government Scientific Office, the NIHR’s Biomedical Research Centres and Clinical Research Facilities, and expert centres in Northern Ireland, Scotland and Wales, clinical research company IQVIA and biopharmaceutical company AstraZeneca.
Professor Tom Wilkinson, ACCORD clinical academic lead based at the NIHR Southampton Biomedical Research Centre, said:
“There has been a tremendous effort to pull this initiative together so rapidly. ACCORD is a national effort and will be key to developing effective new treatments which are needed so desperately.”
“The ACCORD platform will be able to rapidly test potential new treatments, advancing the most promising through phase 2 clinical trials into the NHS. This unique national platform for developing new COVID-19 drug candidates will access the world-class expertise and resources of the NIHR Respiratory Translational Research Collaboration and allied centres nationwide.”
Through the Therapeutic Taskforce, the life science sector can suggest potential drugs or molecules that could be tested through the ACCORD platform. Data will be open source and freely available to enable global knowledge sharing and collaboration.
Dr Jonathan Sheffield, NIHR COVID-19 Research Operations Director said:
“ACCORD will transform the way in which the UK’s research community finds treatments for global healthcare challenges such as COVID-19. ACCORD is an exemplary case of government, industry and research organisations working together with urgency, to the benefit of patients and the NHS.”
“The NIHR’s experimental medicine infrastructure of people, facilities and technology is well-placed to fast-track research into COVID-19 treatments.”
In addition to the first drugs being tested, the Therapeutics Task Force continues to identify potential early stage drugs to be trialled through the ACCORD platform.
IQVIA is providing a national, single platform to ACCORD and will deliver the trials via NIHR’s world-class network of investigators and research facilities, and partners sites in Northern Ireland, Scotland and Wales. AstraZeneca will work with the pharmaceutical industry to scope and support rapid upscaling of development and trials.
Tim Sheppard IQVIA UK GM and SVP Northern Europe said:
“COVID-19 is the greatest public health challenge that has faced the world in a generation. Hyper-accelerating clinical trials of medicines in discovery pipelines could be instrumental in saving many lives in the UK and beyond.”
“IQVIA is proud to be able to mobilise our platform and use our vast network of clinical trial infrastructure, research expertise and data analytics to work with the ACCORD partners to develop treatments that can change the course of this pandemic.”
The first wave of new and existing medicines to be tested through the ACCORD-2 platform are:
For further info on the BerGenBio compound, please contact Richard Godfrey, CEO of BerGenBio, at media@bergenbio.com.
Our ODP Cross-Government Buddy Scheme is here to help increase student support for those undertaking an ODP qualification.
We understand that everyone learns differently so we offer this scheme as an option to those who feel they would benefit from further support during their qualification journey.
For those who have completed their qualification already, this is an exciting opportunity to develop your skills and knowledge, by leading and managing candidates, whilst working collaboratively across different government departments.
Buddies will offer additional support and guidance to people who are currently undertaking the same level of qualification that they have previously completed. It is an informal support network that will be carried out in a way that the buddy and candidates agree suits everyone best.
In this pack we will outline what you can expect from the Buddy Scheme and explain how you can get involved if you haven’t done so already.
Buddies
Candidates
ODP Central Team
If you have not yet registered yourself onto the LISTR tool you will need to do this in order to start your buddy/candidate journey, you can do this by clicking here – Listr tool – Register and entering your email address and a password and clicking “register my account”
To register as a buddy: If you are interested in registering as a buddy all you need to do is register yourself on LISTR. During the registration process you will be asked if you would like to be a buddy and which ODP qualification you have completed. Once you are registered on LISTR candidates can directly request you as their buddy – you will be given the option to accept or decline any candidates.
To register as a candidate: If you are interested in matching with a buddy to help you with your qualification, please follow our quick guide below once you have registered on LISTR
Once you have found a suitable match and have contacted them direct, we would advise that you arrange a time/date suitable for you both to review where the candidate is currently up to with their qualification and how the buddy feels they could support the candidate best.
Before starting this process have a think about what you would like to get from the scheme and make a note of any ideas you might have about how you can contribute and ways you can communicate across government.
Buddies should think about how much time you can dedicate and what support you can offer. Consider practical issues, such as how you would prefer your candidate group to contact you?
We would recommend that candidates remain with the same buddy for the duration of their qualification, as a minimum. Hopefully you will remain in contact with your buddy/candidate following completion of their qualification however, offering continuous development and support across government as your careers progress.
Please remember that the Buddy Scheme is flexible in order to accommodate all and will develop depending on the requirements of the individuals involved. It’s up to you to decide how you wish to communicate, how often and what forums you may use.
It is important that you get what you need from your buddy so please come to all meetings arranged by your buddy fully prepared. You may wish to consider pulling together any questions/issues you are having with your qualification and sending them to your buddy prior to these meetings. This would enable your buddy to ensure they are equipped to answer all of your questions.
Once you have received contact from your candidates, we recommend that an initial telekit is arranged by you to introduce yourself, from here you can decide how you both wish to proceed. A suggested agenda for the first chat is:
Both We’ve included below a list of things that could be considered by buddies and candidates when arranging their meetings:
Plagiarism is defined as “presenting someone else’s work, in whole or in part, as your own. Work means any intellectual output, and typically includes text, data, images, sound or performance”. (University of Leeds, 2017)
It is important that everybody fully understand what plagiarism is and the techniques that can be used to avoid plagiarising. For units with written assignments candidates will be asked to submit a statement of authenticity confirming that the work being submitted is their own. When submitting any work (including exam papers) electronically candidates are also declaring that the work is authentic and is their own.
In cases where plagiarism is identified these will be investigated further by Premier Partnership and City & Guilds and may result in candidates being disqualified from the qualification itself. Plagiarism and malpractice will not be tolerated, any incidents will also be reported to candidates departments and may result in disciplinary action.
Candidates- Please visit The University of Leeds – Academic Integrity & Plagiarism page before starting your qualification and familiarise yourself with the information available.
We would also recommend completing the You Be the Judge activity and Recognising Plagiarism to test your understanding.
If you anybody is still unsure what constitutes plagiarism, or would like to discuss this further, please don’t hesitate to contact the ODP Central Team learningandaccreditationteam.centralodp@hmrc.gov.uk.
FAQ’s
Q: I’ve completed one qualification already and started my second. Can I take part as a buddy and a candidate at the same time?
A: Yes, if you’d like to support others with the qualification you have completed but would also like to join a group who are undertaking the same qualification as you this is fine.
Q: What do I do if I no longer want to take part in the scheme?
A: If you’re a candidate please discuss this with your buddy at the earliest opportunity. Involvement in the scheme is not mandatory, if at any time you wish to withdraw you can. If you are a buddy please contact your candidate and tell them of your decision to enable them to contact potential new buddies at their earliest convenience.
Q: As a buddy how much time will I need to dedicate to this? I’m worried that I won’t be able to fit this in around my day job…
A: How much time you put in is entirely up to you, however the more you put in, the more you will get out of it. As a buddy you’ll be facilitating and encouraging your candidates. How you chose to support your candidates will depend on what you decided between yourselves. For example, you may decide to offer a monthly dial in for an hour or set up an online forum where you can manage and answer queries as they are raised.
For help and support with learning please email learningandaccreditationteam.centralodp@hmrc.gov.uk
For help with LISTR/Account issues please use the “help” button at the top of the Listr tool – Register